Alimera Sciences Announces Participation at the 11th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 17, 2020
Alimera Sciences (NASDAQ: ALIM) has announced that its President and CEO, Rick Eiswirth, will participate in the Craig-Hallum Capital Group’s annual Alpha Select Conference on November 17, 2020. This event will focus on one-on-one and small group meetings conducted via video conference. Alimera specializes in prescription ophthalmic treatments aimed at retinal diseases, addressing significant needs in an aging population where current therapies are lacking. For more information, visit www.alimerasciences.com.
- None.
- None.
ATLANTA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will participate in the Craig-Hallum Capital Group’s annual Alpha Select Conference on Tuesday November 17, 2020. The conference consists of one-on-one and small group meetings, which will take place via video conference.
Attendees of the conference can schedule a meeting with Mr. Eiswirth here.
About Alimera Sciences, Inc.
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.
| For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com | For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com |
FAQ
What event will Alimera Sciences participate in on November 17, 2020?
Who is the CEO of Alimera Sciences?
What does Alimera Sciences specialize in?
